Trial NCT04504032
Publication Ananworanich J, Clin Infect Dis, 2021
Primary outcome on the report: Safety: frequency of adverse events (AEs) including Grades 3 and 4, resulting in discontinuation, serious AEs and hypersensitivity and major bleeding events through Day 35. Efficacy: the proportion of participants who progressed to moderate or severe disease category (Gates MRI scale 3 or higher), through Day 28.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.